Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.h

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Although not all authors will agree (PMID 10514017), currently abvailable evidence is consistent with a cause and effect relationship. Drug discontinuation and follow-up upon withdrawal are indicated

Publications

García Pulido B, Molina Campos L, González Justo L, Álvarez Navascúes FJ

[Positive p-ANCA vasculitis associated with antileukotriene treatment].

Atencion primaria. 2021;53(9):102139

Uyar M, Elbek O, Bakır K, Kibar Y, Bayram N, Dikensoy Ö

Churg-Strauss syndrome related to montelukast.

Tuberkuloz ve toraks. 2012;60(1):56-8

Bibby S, Healy B, Steele R, Kumareswaran K, Nelson H, Beasley R

Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database.

Thorax. 2010;65(2):132-8

Kaliterna DM, Perković D, Radić M

Churg-Strauss syndrome associated with montelukast therapy.

The Journal of asthma : official journal of the Association for the Care of Asthma. 2009;46(6):604-5

Nathani N, Little MA, Kunst H, Wilson D, Thickett DR

Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective.

Thorax. 2008;63(10):883-8

Harrold LR, Patterson MK, Andrade SE, Dube T, Go AS, Buist AS, Chan KA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R, Walker AM

Asthma drug use and the development of Churg-Strauss syndrome (CSS).

Pharmacoepidemiology and drug safety. 2007;16(6):620-6

Lilly CM, Churg A, Lazarovich M, Pauwels R, Hendeles L, Rosenwasser LJ, Ledford D, Wechsler ME

Asthma therapies and Churg-Strauss syndrome.

The Journal of allergy and clinical immunology. 2002;109(1):S1-19

Wechsler ME, Pauwels R, Drazen JM

Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?

Drug safety. 1999;21(4):241-51

Green RL, Vayonis AG

Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment.

Lancet (London, England). 1999;353(9154):725-6